Is the paternal mononuclear cells' immunization a successful treatment for recurrent spontaneous abortion?
Am J Reprod Immunol 2000 Sep;44(3):129-35 (ISSN: 1046-7408)
Ramhorst R; Agriello E; Zittermann S; Pando M; Larriba J; Irigoyen M; Cortelezzi M; Auge L; Lombardi E; Etchepareborda JJ; Contreras Ortiz C; Fainboim L
Division Immunogenetica, Hospital de Clinicas, Facultad de Medicina, UBA, Buenos Aires, Argentina.
Alloimmunization as a treatment for recurrent spontaneous abortion (RSA) is still controversial due to the lack of enough controls to evaluate its effectiveness. The present study was conducted to compare the live birth rate in the presence or absence of immunotherapy.
METHOD OF STUDY:
Ninety-two women with RSA (79 primary [PA] and 13 secondary aborters[SA]) received immunotherapy. Thirty-seven RSA couples not receiving paternal alloimmunization, constituted the "control" group.
The pregnancy rate in alloimmunized was 58 vs 46% in the control group. The live birth increased from 71% in the controls to 88% after immunotherapy. The alloimmunization induced mixed lymphocyte reaction blocking factors (MLR BFs) in 79% of women. However, they were also present in 83% of immunized women experiencing a new abortion.
These results indicate that alloimmunization may be useful in the treatment of RSA.